Technical Analysis for KPTI - Karyopharm Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 15.44 -1.03% -0.16
KPTI closed down 1.03 percent on Monday, November 18, 2019, on 72 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
6 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical KPTI trend table...

Date Alert Name Type % Chg
New 52 Week High Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week Closing High Bullish -1.03%
New 52 Week High Strength -1.03%
Wide Bands Range Expansion -1.03%
Overbought Stochastic Strength -1.03%
NR7 Range Contraction 0.55%
Inside Day Range Contraction 0.55%
Wide Bands Range Expansion 0.55%

Older signals for KPTI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
KPTI Chart by TradingView
Basic chart:
Profile
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.
Medicine Cancer Pharmaceutical Diseases Treatment Of Cancer Oncology Chemotherapy Occupational Safety And Health Antibody Drug Conjugates Pixantrone
Is KPTI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 13 BofAML likes Alnylam in premarket analyst action
Nov 13 The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Nov 12 The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Nov 9 Edited Transcript of KPTI earnings conference call or presentation 4-Nov-19 1:30pm GMT
Nov 6 Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
Nov 6 Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%
Nov 6 3 Names Making the Case That Investing in Small Biotech Is Never Dull
Nov 5 Karyopharm Therapeutics: Up, Up And Away
Nov 5 The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment
Nov 4 Karyopharm Therapeutics Inc.'s (KPTI) CEO Michael Kauffman on Q3 2019 Results - Earnings Call Transcript
See more KPTI news...
Indicators
Indicator Value
52 Week High 15.8
52 Week Low 3.92
Average Volume 1,602,034
200-Day Moving Average 7.847
50-Day Moving Average 11.5828
20-Day Moving Average 13.3168
10-Day Moving Average 14.9585
Average True Range 0.6804
ADX 53.8
+DI 34.5551
-DI 5.6307
Chandelier Exit (Long, 3 ATRs ) 13.7588
Chandelier Exit (Short, 3 ATRs ) 12.5712
Upper Bollinger Band 16.823
Lower Bollinger Band 9.8106
Percent B (%b) 0.8
BandWidth 52.658296
MACD Line 1.2974
MACD Signal Line 1.1288
MACD Histogram 0.1686
Fundamentals Value
Market Cap 727.81 Million
Num Shares 47.1 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -5.74
Price-to-Sales 2836.82
Price-to-Book 2.82
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.15
Resistance 3 (R3) 16.19 15.99 16.03
Resistance 2 (R2) 15.99 15.81 15.97 15.99
Resistance 1 (R1) 15.72 15.70 15.62 15.68 15.95
Pivot Point 15.52 15.52 15.48 15.50 15.52
Support 1 (S1) 15.25 15.34 15.15 15.21 14.93
Support 2 (S2) 15.05 15.23 15.03 14.89
Support 3 (S3) 14.78 15.05 14.85
Support 4 (S4) 14.74